Gumus, MahmutChen, Chieh-, IIvanescu, CristinaKilickap, SaadettinBondarenko, IgorOzguroglu, MustafaGogishvili, MirandaTurk, Haci M.Cicin, IrfanHarnett, JamesMastey, VeraNaumann, UlrikeReaney, MatthewKonidaris, GerasimosSasane, MedhaBrady, Keri J. S.Li, SiyuGullo, GiuseppeRietschel, PetraSezer, Ahmet2023-09-192023-09-1920230008-543Xhttps://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.34477http://hdl.handle.net/11727/10694Background In the EMPOWER-Lung 1 trial (, NCT03088540), cemiplimab conferred longer survival than platinum-doublet chemotherapy for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%. Patient-reported outcomes were evaluated among trial participants. Methods Adults with NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. At baseline and day 1 of each treatment cycle, patients were administered the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 (QLQ-C30) and Lung Cancer Module (QLQ-LC13) questionnaires. Mixed-model repeated measures analysis estimated overall change from baseline for PD-L1 >= 50% and intention-to-treat populations. Kaplan-Meier analysis estimated time to definitive deterioration. Results In PD-L1 >= 50% patients (cemiplimab, n = 283; chemotherapy, n = 280), baseline QLQ-C30 and QLQ-LC13 scores showed moderate-to-high functioning and low symptom burden. Change from baseline favored cemiplimab on global health status/quality of life (GHS/QOL), functioning, and most symptom scales. Risk of definitive deterioration across functioning scales was reduced versus chemotherapy; hazard ratios were 0.48 (95% CI, 0.32-0.71) to 0.63 (95% CI, 0.41-0.96). Cemiplimab showed lower risk of definitive deterioration for disease-related (dyspnea, cough, pain in chest, pain in other body parts, fatigue) and treatment-related symptoms (peripheral neuropathy, alopecia, nausea/vomiting, appetite loss, constipation, diarrhea) (nominal p < .05). Results were similar in the intention-to-treat population. Conclusions Results support cemiplimab for first-line therapy of advanced NSCLC from the patient's perspective. Improved survival is accompanied by improvements versus platinum-doublet chemotherapy in GHS/QOL and functioning and reduction in symptom burden.enginfo:eu-repo/semantics/openAccesscemiplimabnon-small cell lung cancerpatient-reported outcomesquality of lifesymptom burdenarticle12911181290008756636000012-s2.0-85141409577